Long wait times for biologic prescriptions, insurance requests for more records, and staff busy chasing prior authorizations. It would be a huge help if an administrative service focused on Prior Authorization could handle that work, assuming they do the parts of the job your service actually requires.
The right partner clearly outlines requirements. They prepare submissions and track decisions. They link treatment authorizations to case management and cash flow. When comparing options, an approval rate is a weak proxy for the quality of a prior authorization service. Ownership of cases is also important. You need to understand which activities the provider will cover, which activities the dermatologist will perform, and the cases which remain unmanaged.
Outsourcing Prior Authorization Coordination to a Specialist is a Good Idea
Prior authorization services, in the scope of their work, can perform benefit verification, collect and assemble the required evidence, prepare submissions, track and follow-up on decisions, renewals and/or appeals. The contract should outline the scope of work.
In most cases, an outsourced prior authorization coordinator can assist in organizing and collecting clinical records to support your case for treatment, but ultimately it is your dermatologist that remains responsible for the assessment and rationale for prescribing the treatment.
| Service component | Deliverable your practice should receive |
|---|---|
| Requirement verification | Confirmation of whether PA is required for the memberโs plan and requested service |
| Benefit routing | Identification of the medical plan, pharmacy benefit manager, or delegated reviewer |
| Submission preparation | A completed request supported by relevant, clinician-approved documentation |
| Payer follow-up | Visible status, outstanding requirements, a responsible owner, and the next action |
| Denial support | Recorded reasons, applicable response requirements, and an evidence packet for clinical review |
| Renewal coordination | An active work queue for approvals approaching expiration and required continuation evidence |
| Billing or pharmacy handoff | Approval details delivered to the team that must use them |
Determine whether eligibility verification, specialty-pharmacy coordination, and appeals are discrete services. A submission-only option would work for a practice with robust internal follow-up; otherwise, it would leave a big gap, with the assumption that the vendor also handles cases that are pending.
According to the 2020 AMA survey, almost 40 percent of practices had staff solely dedicated to prior authorization. Though this data reflects multiple specialties rather than just dermatology, it explains the rationale behind practices considering dedicated support.
Authorization Requires Specific Items
There is no universal dermatology authorization list. Requirements vary based on the memberโs insurance, the memberโs benefit, the memberโs diagnosis, the memberโs treatment, the memberโs formulation, and the setting. A published policy on medical necessity may render prior authorization for a given member.
Biologics and Specialty Medications
Adalimumab, dupilumab, and secukinumab are examples of medications that require prior authorization for the treatment of various inflammatory conditions, like psoriasis, atopic dermatitis and hidradatitis suppurativa. Prior authorization for psoriasis and atopic dermatitis can vary by indication and policy. The pathway to coverage may vary by the product and how it is supplied and/or administered.
There is a significant difference between self-administered and office-administered medications. Office-administered medications may follow the medical benefit, while self-administered medications may follow the pharmacy benefit. Staff should check the pathway to determine the reviewer and specialized pharmacy, as well as what method of payment may be appropriate.
| Treatment or service | Authorization considerations |
|---|---|
| Self-administered biologics | Drug-specific criteria, preferred products, step therapy, quantity limits, and specialty-pharmacy requirements |
| Office-administered specialty drugs | Medical benefit rules, product and administration codes, units, provider, and treatment setting |
| Prescription topicals and oral agents | Formulary status, diagnosis, formulation, quantity, and any required treatment trials |
| Isotretinoin | Payer requirements plus separate compliance with the FDAโs iPLEDGE REMS |
| Phototherapy or photodynamic therapy | Covered indication, requested treatment, authorized sessions or units, and renewal evidence |
| Mohs surgery and selected excisions | Member-specific requirements, intended procedure, diagnosis, anatomical site, and performing provider |
| Laser or lesion treatment | Benefit exclusions and documented medical indications, including the distinction from cosmetic treatment |
Reviewing clinical details can impact coverage decision outcomes
Differences in Aetna’s published criteria for Dupixent, compared to a generic โsevere eczemaโ criteria, illustrate the value of capturing specific details. Aetnaโs atopic dermatitis criteria focuses on the body surface area/zonality of the affected area(s). They also consider the individualโs treatment history and other relevant medical conditions. Coverage for a small affected area does not necessarily mean the requirement has been satisfied. The applicable member policy must still be confirmed.
Separate checks for isotretinoin and cosmetic exclusions are needed
There are differences in FDA regulations for isotretinoin and insurance approval. Prescribers, Pharmacies, and Patients must each have an iPLEDGE account to participate. Approval by the payer does not necessarily mean the prescription can be dispensed.
A cosmetic exclusion policy, like that for the removal of benign lesions, for example, notes that certain symptoms and/or clinical circumstances are to be considered in determining medical necessity. Authorizations teams cannot change or add symptoms to a request to treat a diagnosis for which coverage is being sought.
The workflow between treatment order and approval
To make a process repeatable, each request must have an owner, evidence to support the request, and a defined next step. The following helps illustrate where a process stalls in the practice, payer, and pharmacy.
1. Confirm coverage, and the detail required
Maintain distinctions for eligibility, referral, network participation and authorization. An active policy does not confirm a clinician participates in the product, and a referral may not satisfy a PA requirement.
Ensure to document the source of requirement and payer reference. Maintain evidence of payer confirmation of authorization for a given member for the given service.
2. Reroute the request to the appropriate reviewer
Identify the organization (medical plan, pharmacy benefit manager, or other delegated entity) responsible for the decision regarding the request, and route the request appropriately. A biologic request routed to the incorrect reviewer will remain unresolved, even with complete documentation.
Confirm with the reviewing entity the required specialty pharmacy, the product, formulation and dose, loading and maintenance regimens, and the quantity to be dispensed. For an office-administered drug, confirm the acquisition and billing arrangement prior to the practice assuming inventory risk.
A general eligibility response should not be assumed as authorization. Electronic requests for medications and medical services can be processed by different systems; one system does not handle all requests.
3. Amass appropriate evidence for the policy
A clinical documentation gap, as identified by the policy, should be addressed by the clinician and sent to the coordinator. Evidence may include:
- The diagnosis and supporting assessment
- Location, severity, and impact
- Prior treatment and response
- Intolerance and/or contraindication
- Test results, pathology, photos, other relevant evidence
- Product, dose, formulation, quantity, and procedure
โFailed topicalsโ usually provides insufficient information for a required trial. Some organization of the existing treatment history is useful. Inventing a required trial is not. The rationale for step-therapy exceptions is documented in the clinicianโs judgment. Similarly, clinical judgment is used to determine which tests and treatments are appropriate.
4. Submit accurately and retain receipt evidence
Use the channel preferred by the responsible reviewer. Check patient IDs, prescribers, service codes, requested quantities, and review the attached evidence prior to submission.
Retain the submitted evidence and proof the payer received it. A fax cover sheet or drafted request should not be indistinguishable from a submitted request. A submitted request should not be in the queue, unless the payer directs otherwise.
If the payer requests additional information, the question should be verbatim. Staff should determine the case for an expedited request. The administrative team should be able to trace a case without reconstructing it.
5. Keep patients and staff updated
Use detailed statuses to update the team. The team needs to know the justification for an expedited request and how it was communicated to the payer.
Staff should evaluate the patientโs condition and determine if it requires the request be expedited. Alternative and interim treatment choices are clinical judgement. Worsening symptoms require clinical assessment. Patients should be directed to the clinical team if they have concerns about treatment or if they are suffering adverse effects from current treatment.
6. Close the loop with treatment and billing
Once you have received the authorization, note down the approved item/service, quantity, dates, provider, site, and reference number. Inform the specialty pharmacy, scheduling department, and medical billing services about the approval so all can act accordingly on the same approval.
Even before starting the treatment, make sure the pharmacy is able to dispense the medication or procedure can be done based on the approved benefit. The authorization could be subject to network restrictions or affordability or other coverage restrictions as well.
In the case of renewal, take care of the clinical baseline of the patient along with the continuity of records needed by the payer. In case the insurance of the patient has been changed, check the requirements of the new plan.
Preventing the Denials Your Team Can Control
Some denials reflect benefit exclusions or a disagreement about coverage criteria. Others arise from correctable administrative problems. Reporting them separately helps the practice decide where to improve its process.
| Problem | Practical control |
|---|---|
| Request sent through the wrong benefit | Confirm the responsible reviewer before submission |
| Prior treatment history is unclear | Organize named therapies, outcomes, and supporting records |
| Requested product differs from the approved product | Check formulation, preferred product, dose, and quantity |
| Claim uses a different provider or location | Match the intended billing arrangement against the approval |
| Authorized sessions are exhausted | Track utilization alongside remaining approval limits |
| Cosmetic exclusion or unsupported indication | Review the benefit and actual clinical documentation |
Investigations for authorization and claim denials are different. Authorization denials require an evaluation of the review reason and available correction, exception, peer review, or appeal pathway. Claim denials require an analysis of the billed service, compared to the approval, and the payerโs explanation.
A peer-to-peer discussion may be available, but it should not be assumed that a discussion will replace a formal appeal and/or preserve appeal rights. Document the payerโs instructions and requirements for each pathway. The clinician makes the medical argument. The administrative staff can collect and present the evidence and arrange for the discussion.
The AAD offers an appeal letter tool with drug-specific rationales. The tool, templates and examples, provide a starting point. It still requires patient-specific evidence, and clinician input and review.
Case in point: A biologic request is denied with the denial notice only saying โprevious treatment unsuccessful.โ The denial notice does not say what biologic is being requested or provide any justification. The denial notice only states the treatment was unsuccessful. The coordinator asked the clinical staff for clarification and referred to the signed record where the requested medication was documented, along with a stated intolerance to the medication. The next step is to identify the payerโs permitted correction or appeal route, and arrange a clinical review. If justification is lacking, the case is referred back to the clinician. Repeatedly submitting the same form does not resolve the reason for the denial.
Get Your Staff a Well-defined PA Work Process
Find out where requests get stuck between clinical documentation, payer evaluation, and billing. HMS USA can talk about a range of support services based on your dermatology practice needs and staffing.
In-House, Outsourced, or Shared: Choose by Workload
While an in-house team can collaborate well with dermatologists and get their issues sorted out quickly, it needs appropriate training, coverage, and current information about payer policies. In case there are different duties related to prior authorizations divided among the reception, nursing, and billing personnel, there can be confusion and mistakes can happen.
When outsourcing, the practice gets special assistance with the authorization and documentation process. Together with good Dermatology Billing Services, outsourcing can result in more efficient communication between all departments. The outcomes will depend on the extent of outsourced duties and regular reporting from the external service.
| Factor | In-house team | Outsourced team |
|---|---|---|
| Clinical clarification | Direct access to treating staff | Needs a defined escalation contact |
| Staffing coverage | Depends on available trained employees | Depends on the vendorโs assigned team and backup arrangements |
| Payer knowledge | Develops around the practiceโs patient mix | Must demonstrate knowledge of your actual plans and services |
| Status visibility | Depends on internal tracking | Requires access to case-level records and reports |
| Quality oversight | Practice manages staff performance | Practice must review vendor work and contract performance |
A shared model often makes sense: the outside team verifies requirements, organizes records, submits requests, and follows status, while a designated clinical contact resolves medical questions. The practice can retain patient communication or specialty-pharmacy coordination if those relationships are already working well.
Define the handoff explicitly. A missing clinical note needs a named recipient and an escalation route. Sending a message to a shared inbox does not establish that someone has accepted responsibility.
Comparing Cost, Turnaround, and Revenue on Equal Terms
Scope of work pricing
The quote can apply to completed work, staffing, a continuing service bundle, or work covered by another billing package. What’s important is knowing what the money buys.
Find out whether the quote covers benefit validation, answering for additional information, denial management, appeal management, renewals, specialty pharmacy interaction, and reconciliation with billing. Be sure that a new case, corrected case, or change of therapy constitutes additional charge.
In order to make an internal comparison, account for compensation, benefits, software expenses, training, supervision, and any remaining work done internally. Add the outside service vendor fees for comparison to internal coordination, review, and any other services which are not provided externally.
Illustrative calculations only, not market price: a batch of 120 completed cases comes at a cost of $3,000, or $25 per case, done internally. An outside quote of $2,400 with $900 worth of remaining internal work costs $3,300, or $27.50 per case. There may be value added by an outside quote, however, in capacity or coverage, but only a quote itself doesn’t reflect all costs of operations.
Distinguish Practice Performance from Payer Decision
The service can handle the intake, the preparation, the submission, and the follow-ups. It canโt make any promises about the decision by the payer or the approval.
For turnaround comparisons, request individual indicators for preparation, payer review, and follow-up after an additional information request. Consider the pending cases; just reporting the straightforward approvals would be misleading.
CMS separates the requirements for particular medical products/services from the drug-related requests for interoperability/PA. There are also different responsibilities for the plan types. The partner should consider which pathway applies to the member rather than providing a blanket answer.
Measure Access and Financial Performance
Good reports can include completion of submissions, initial approval rate, appeal outcomes, aging of open cases, pre-expiration renewals, and claim denials due to authorization issues. Define all denominators. An initial approval rate needs to be different from a final approval rate which accounts for successful appeals.
For instance, 72 initial approvals over 90 initial decisions yield 80 percent. Ten more outstanding applications need to be presented alongside this ratio. To refer to the entire backlog as โ80 percent approvedโ will obscure the distinction between the two.
Match authorization cases to prescription filling, procedure completion, and claims outcomes if available. An authorized request is one of the access achievements while revenue collection depends on the next milestones. Separate delayed amounts from write-offs and do not double count a recovered claim as new income.
HIPAA and Automation Require Practical Supervision
A PA vendor acting as a business associate under HIPAA rules will usually process protected health information on behalf of the covered practice. The HHS guidelines discuss the necessity for a proper business associate agreement and what is required from business associates and their relevant subcontractors.
Consider how the partner gets access to the records, keeps the documents, uses subcontractors, and reports incidents. The agreement should provide for proper access, proper uses of the information, and proper handling of the patient records.
The practical issues are such as whether there are individually assigned accounts, how the access is terminated, what authentication features the systems allow, and how the submission activity can be tracked. Clinical photos and document extracts must get equal treatment to the rest of the patient records.
Automation can help in organizing the documentation, populating fields, highlighting gaps in documentation, and routing tasks. This process needs to be checked with reference to the source document and payer requirements. The software must not assume a treatment failure in the absence of a documented treatment failure, make a clinical determination, or choose urgency without a clinical reason.
In case of AI being used, state where the patient data will be processed and its use permitted in the situation. Mere marketing statement on HIPAA compliance or security certification cannot be substituted for your assessment of the arrangement.
Choose a Dermatology Prior Authorization Service with Clear Ownership
A walk-through of a de-identified case scenario similar to your workflow would be the best vendor demonstration. A single ask may not reflect how the team handles a missing patient history, prescription change, denial, or an upcoming expiration.
These are some questions to use during proposal review:
- Workflow expertise: Does the team understand biologic, topical, phototherapy, and procedural workflows specific to your workflow?
- Benefit verification: Who verifies the right reviewer, specialty pharmacy, and the relevant coverage policy?
- Clinical parameters: Who identifies missing evidence and who from your practice provides the clinical solution?
- Case ownership: Who manages the open cases, and what is their follow up process?
- Reporting capabilities: Can you have visibility to case status, payer references, missing documentation, next steps, and case outcomes?
- Fee schedule and exclusions: What triggers extra fees and when is a case closed?
- Data management and continuity of care: What can your practice export, and how are open cases managed when relationship terminates?
Effective documentation will make it obvious what the next step should be. This could include for example in an eczema fiction case: benefit in the pharmacy verified; clinician feedback required on previous treatment documented; clinical contact designated; submission pending such feedback. More meaningful than just “pending” with a target approval rate.
Choose performance measures appropriate to the payers you deal with and the complexity of your cases. The comparisons should reflect initial determinations, appeals, and work-in-progress. A good vendor working another set of cases may boast a great approval rate that means nothing to you.
Relating Authorization Services to the Role of HMS USA RCM Services
HMS USA offers services for billing, coding, credentialing, denials management, and accounts receivable. In case of authorization support by a dermatology practice, the process will entail the medications, procedures, payer products, systems, and roles involved.
The main aim here would be to establish reliable transition from the clinical chart to authorization submission, after which pharmacy coordination or procedure scheduling/billing follow. There must be an owner for each exception; there could be missing documentation, enrollment issues, product mismatches, and payer denials.
There must also be a definition of what the practice would continue doing and what would the managers get in terms of reporting. Diagnosis, therapy decision, and clinical judgment must lie with the physicians. Approval and payments will depend on the coverage and policies of the payer.
Create a More Effective Authorization Process
Discuss how your payer mix, most frequent procedures, and outstanding authorization challenges will affect your decision-making process when speaking to HMS USA. Understand what type of administrative support and billing processes you need prior to scope selection.
Frequently Asked Questions
Which dermatology treatments may require prior authorization?
Depending on the plan, PA may apply to biologics, prescription topicals, oral medications, phototherapy, Mohs surgery, selected excisions, and certain laser treatments. Requirements vary by member, product, diagnosis, and setting. A coverage policy alone does not establish that authorization is required.
Can a service guarantee faster approval?
A service can improve preparation, submission accuracy, and follow-up, but the insurer controls its coverage decision. Compare administrative performance separately from payer review. Requests requiring further clinical evidence, exceptions, or appeals should remain visible in the performance report.
Can the same team handle medication and procedure requests?
Yes, if both are included in its scope and expertise. Pharmacy benefit and medical benefit requests can involve different reviewers, criteria, systems, and documentation. Verify that the team supports both pathways rather than assuming one submission process covers every dermatology service.
Does an approved authorization guarantee payment?
No. Cignaโs provider guidance explicitly distinguishes precertification from a payment guarantee. Eligibility, benefits, actual services, provider arrangements, and claim accuracy still matter. Billing staff should verify that the claim corresponds to the authorized service and investigate any remaining coverage requirements.ย
Can an outsourced team handle appeals?
It can organize records, track response requirements, prepare administrative materials, and coordinate reviews within the agreed scope. Clinical arguments and discussions requiring a qualified treating professional remain with the appropriate clinician. Confirm whether appeal preparation is included or separately charged.
Can a practice outsource PA without changing its EHR?
Potentially. Some arrangements use the practiceโs existing systems and approved portal access. Compatibility, permissions, auditability, and record export need confirmation. The agreement should specify where information is recorded so the clinical, authorization, and billing teams can find it.
A dermatology prior authorization service earns its place by making each case easier to act on. Clear scope, accurate evidence, visible ownership, and reliable handoffs give practice managers a stronger basis for judging performance than a promise about approvals alone.
ย





